Widespread use of measurable residual disease in acute myeloid leukemia practice
Precursor Cell Lymphoblastic Leukemia-Lymphoma
MRD was frequently used in making treatment decisions and in estimating prognosis. However, there was lack of uniformity in these practices. Standardization of assays, adoption of requisite technology, and dissemination of data about the value of MRD use would likely increase usage of MRD in the care of patients with AML.